Dinutuximab
| Dinutuximab | |
|---|---|
| Term | Dinutuximab |
| Short definition | Dinutuximab - (pronounced) (din-yoo-TUK-sih-mab) drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has improved with other cancer treatments. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Dinutuximab - (pronounced) (din-yoo-TUK-sih-mab) drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. It is used in patients whose disease has improved with other cancer treatments. Dinutuximab attaches to a substance called GD2, which is found on some types of cancer cells. Dinutuximab can block GD2 and help the immune system kill cancer cells. It's a type of monoclonal antibody. Also called Ch14. 18, MOAB Ch14. 18, monoclonal antibody Ch14. 18 and Unituxin
External links
- Medical encyclopedia article on Dinutuximab
- Wikipedia's article - Dinutuximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski